The FDA approved Merilog (insulin-aspart-szjj) as the first biosimilar to reference Novolog (insulin aspart) for the treatment of adult and pediatric patients with type 2 diabetes. In 2024, the FDA ...

The first 10 drugs targeted for negotiations were announced the following year — Novo’s rapid-acting insulin medication NovoLog among them — and new prices, agreed upon in 2024, are set to take effect ...